BTI.V - Bioasis Technologies Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.3600
-0.0200 (-5.26%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Previous Close0.3800
Open0.3700
Bid0.3550 x 0
Ask0.3700 x 0
Day's Range0.3600 - 0.3850
52 Week Range0.1400 - 0.4000
Volume10,894
Avg. Volume47,957
Market Cap22.886M
Beta (5Y Monthly)0.61
PE Ratio (TTM)N/A
EPS (TTM)-0.0650
Earnings DateJan. 29, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bioasis and Chiesi Group to Host Webcast on July 16, 2020
    Business Wire

    Bioasis and Chiesi Group to Host Webcast on July 16, 2020

    BIOASIS TECHNOLOGIES INC. ("Bioasis") (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit of Chiesi Group, an international research-focused healthcare Group, today announced that the companies will host a webcast presentation and conference call at 1:30 p.m. EDT on Thursday, July 16, 2020 to discuss the previously announced Rare Diseases Strategic Alliance.

  • Business Wire

    Bioasis Announces Stock Option Grants

    BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,495,000 common shares effective June 30, 2020 at a price of $0.31 per share to directors and officers of the company. All of the options expire five years from the date of the grant and are governed by the terms of the company’s stock option plan. The options are being issued as part of annual remuneration.

  • Business Wire

    Bioasis Announces Filing of Its Fourth Quarter and Fiscal Year-End Financial Statements and MD&A

    BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced it has filed its audited annual financial statements and management’s discussion and analysis for the period ended February 29, 2020. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us/investors/.

  • CNW Group

    IIROC Trading Resumption - BTI

    IIROC Trading Resumption - BTI

  • Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance
    Business Wire

    Bioasis and Chiesi Group Announce Rare Diseases Strategic Alliance

    BIOASIS TECHNOLOGIES INC. ("Bioasis") (TSXV:BTI.V; OTCQB:BIOAF),a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (the "BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including rare genetic diseases, brain cancers, neurodegenerative diseases and pain, and Chiesi Global Rare Diseases, a business unit of Chiesi Group, an international research-focused healthcare Group, today announced that they have entered into a worldwide, exclusive licensing agreement for the xB3 BBB platform technology in treatment of rare diseases with a focus on four undisclosed lysosomal storage disorders ("LSDs").

  • CNW Group

    IIROC Trading Halt - BTI

    IIROC Trading Halt - BTI

  • Business Wire

    Bioasis Announces Conversion of Debenture Interest Into Equity

    BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to satisfy its obligation to pay $26,177.21 in interest to the holders of its 7.5% unsecured debentures issued December 23, 2019 (the "Debentures") as of June 23, 2020 by issuing 104,708 common shares of the Company. The common shares will be issued at a deemed price of $0.25 per share in full satisfaction of the June 23 interest payment obligation in accordance with the terms of the Debentures. The Company chose to settle the interest through the issuance of common shares in order to preserve the amount of cash available to fund ongoing operations while it continues to pursue additional financing opportunities, including potential partnerships.

  • Business Wire

    Bioasis Announces Analyst Coverage Initiated by Edison Group

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSXV:BTI), (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that Dr. Nathaniel Calloway, Healthcare Analyst of Edison Group Inc. ("Edison") has initiated analyst coverage on Bioasis Technologies Inc.

  • Business Wire

    Bioasis Completes Redemption of 15% Unsecured Debentures With Unanimous Debentureholder Approval

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis") a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has completed its previously announced redemption all of its outstanding 15% unsecured debentures issued November 8, 2019 (the "Debentures") at a price equal to 110% of the principal amount of the Debentures (the "Redemption Price"). 100% of the holders of Debentures (the "Debentureholders") agreed to participate in the transaction.

  • Business Wire

    Bioasis Announces Shares for Debt Transaction

    Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to satisfy its obligation to pay $28,076.55 in interest to the holders of its 15% unsecured debentures issued November 8, 2019 (the "Debentures") as of March 31, 2020 by issuing 155,980 common shares of the Company. The common shares will be issued at a deemed price of $0.18 per share in full satisfaction of the March 31 interest payment obligation in accordance with the terms of the Debentures. The Company chose to settle the interest through the issuance of common shares in order to preserve the amount of cash available to fund ongoing operations while it continues to pursue additional financing opportunities, including potential partnerships.

  • Business Wire

    Bioasis Announces Proposed Redemption of 15% Unsecured Debentures

    BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) (the "Company" or "Bioasis"), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it intends to redeem all of its outstanding 15% unsecured debentures issued November 8, 2019 (the "Debentures") at a price equal to 110% of the principal amount of the Debentures (the "Redemption Price"). The Company intends to settle the Redemption Price through the issuance of common shares at a price of $0.20 per share. The aggregate outstanding principal amount of the Debentures is $750,765 and therefore the aggregate Redemption Price is $825,841.50 and the number of common shares to be issued in settlement of the Redemption Price is 4,129,207.

  • Business Wire

    Bioasis Technologies Announces the Appointment of Dr. May Orfali to the Position of Consultant Chief Medical Officer

    Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), (the "Company" or "Bioasis"), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced today the appointment of Dr. May Orfali to the position of Consultant Chief Medical Officer, effective immediately. In this position, Dr. Orfali replaces Dr. Jose Iglesias, who has recently accepted a full-time position at another company. We thank Dr. Iglesias for his contributions to Bioasis to date.

  • CNW Group

    Growth Company Investor Presentations Now Available for On-Demand Viewing

    Growth Company Investor Presentations Now Available for On-Demand Viewing

  • CNW Group

    Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

    Live Investor Conference & Webinar: Growth Company CEOs Present February 20th

  • Investors Who Bought Bioasis Technologies (CVE:BTI) Shares Three Years Ago Are Now Down 83%
    Simply Wall St.

    Investors Who Bought Bioasis Technologies (CVE:BTI) Shares Three Years Ago Are Now Down 83%

    Every investor on earth makes bad calls sometimes. But really bad investments should be rare. So consider, for a...